Avid Bioservices Inc (CDMO)

[pphmtoolong]

goat, Bavituximab is not a fantasy. Peregrine management would not risk submitting a fantasy to Memorial Sloan Kettering and the premier treatment centers of the United States. The simple conclusion is they know they have something in Bavi, and they are eager to let the medical-scientific world determine just how valuable it might be.

The current Peregrine "cycle" as you see it will end soon. Either in success or failure. Based on my years following the Bavi research from the initial patent applications to the latest clinical trials I like the odds of success.

Bavi success will not make me rich. I am already financially independent. It would be nice, and I could blow money on some fun things. However, failure would not affect my current pleasant lifestyle at all.

Those who constantly berate Peregrine's prospects with Bavi do so in the face of considerable data that suggests otherwise.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul